Volume 4.45 | Nov 19

Hematopoiesis News 4.45 November 19, 2013
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
 
TOP STORY
Polycomb Repressive Complex 2 Regulates Normal Hematopoietic Stem Cell Function in a Developmental-Stage-Specific Manner
Researchers prevented assembly of both enhancer of zeste homolog (Ezh) 1- and Ezh2-containing polycomb repressive complex 2 complexes by conditional deletion of embryonic ectoderm development, a core subunit, and assessed hematopoiesis. They found that deletion of Eed exhausts adult bone marrow hematopoietic stem cells (HSCs), although fetal liver HSCs are produced in normal numbers. [Cell]
Abstract | Graphical Abstract
New Cord Banking Software Solution from STEMSOFT
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

A Network of Epigenetic Regulators Guides Developmental Hematopoiesis In Vivo
Investigators identified 15 factors that regulate development of primitive erythroid progenitors and 29 factors that regulate development of definitive hematopoietic stem and progenitor cells. [Nat Cell Biol] Abstract

Mortalin and DJ-1 Coordinately Regulate Hematopoietic Stem Cell Function Through the Control of Oxidative Stress
The inhibition of mortalin function caused abnormal reactive oxygen species elevation in hematopoietic stem cells (HSCs) and reduced HSC numbers. Knockdown of mortalin in hematopoietic stem and progenitor cells impaired their ability to repopulate and form colonies. [Blood] Abstract

Toward a Therapeutic Reduction of Imatinib Refractory Myeloproliferative Neoplasm-Initiating Cells
Although myeloproliferative neoplasms (MPNs) are sensitive to tyrosine kinase inhibitors such as imatinib, patients often relapse upon withdrawal of therapy. Scientists used a model of MPN, which is induced by co-expression of the oncoproteins HIP1/PDGFβR and AML1/ETO from their endogenous loci, to examine the mechanisms of disease development and recurrence following imatinib withdrawal. [Oncogene] Abstract

Proteome Changes Induced by c-myb Silencing in Human Chronic Myeloid Leukemia Cells Suggest Molecular Mechanisms and Putative Biomarkers of Hematopoietic Malignancies
To shed light on the molecular mechanisms associated with aberrant accumulation of c-Myb in chronic myeloid leukemia, comparative proteomic analysis was performed on c-myb RNAi-specifically silenced K562 cells, sampled on a time-course basis. [J Proteomics] Abstract

Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia
Dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors profoundly inhibited growth and survival of acute T-lymphoblastic leukemias cells irrespective of their genetic subtype and their responsiveness to ABL-tyrosine kinase inhibitors. [PLoS One] Full Article

Hsp90 Inhibitor BIIB021 Enhances Triptolide-Induced Apoptosis of Human T-Cell Acute Lymphoblastic Leukemia Cells In Vitro Mainly by Disrupting p53-MDM2 Balance
The authors investigated the effects of BIIB021, an inhibitor of heat shock protein 90 (Hsp90) alone or in combination with triptolide on T-cell acute lymphoblastic leukemia and the mechanisms of action. [Acta Pharmacol Sin] Abstract

CLINICAL RESEARCH

Pre-Transplant Prognostic Factors of Long-Term Survival After Allogeneic Peripheral Blood Stem Cell Transplantation with Matched Related/Unrelated Donors
In this retrospective single-center study of 442 patients with hematologic malignancies, scientists analyzed prognostic factors for long-term survival after peripheral blood stem cell transplantation from HLA-matched related or unrelated donors. [Haematologica] Abstract | Full Article

A Prospective Registration Study to Determine Feasibility of Hematopoietic SCT in Adults with Acute Leukemia: Planning, Expectations and Reality
The European Group for Blood and Marrow Transplantation Acute Leukemia Working Party prospectively followed 695 consecutive patients who were registered at the time of human leukocyte antigen typing. [Bone Marrow Transplant] Abstract

Neutropenia Associated with Anti-Human Neutrophil Antibodies Following Allogeneic Hematopoietic Stem Cell Transplantation
The authors present a case of anti-human neutrophil antigen (HNA) antibody-associated neutropenia following allogeneic hematopoietic stem cell transplantation. By monitoring representative anti-HNA antibodies, the patient showed a variety of anti-HNA antibodies; The authors speculated that the anti-HNA-2 antibody played a crucial role in the development of neutropenia. [Transpl Int] Abstract

A Prospective Multicenter Study of Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure
The EXPLORE study aimed to determine the prevalence of undiagnosed paroxysmal nocturnal hemoglobinuria (PNH) in patients with aplastic anemia, myelodysplastic syndrome, and/or other bone marrow failure syndromes and the effect of PNH clone size on hemolysis. [Cytometry B Clin Cytom] Abstract

Learn more about the new smartphone app for human blood cell frequencies
 
REVIEWS
The Evolving Art of Hematopoietic Stem Cell Transplantation: Translational Research in Post-Transplant Immune Reconstitution and Immunosuppression
The authors review studies of post-transplant immune recovery and approaches to achieve more selective immunosuppressive strategies. [Immunol Res] Abstract

Developmental Changes in Hematopoietic Stem Cell Properties
The authors summarize salient examples of differences in the properties of fetal and adult hematopoietic cells with a particular focus on those that affect or are initiated within the hematopoietic stem cell compartment. [Exp Mol Med] Full Article

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
 
INDUSTRY NEWS
Lundbeck Canada Launches a New Treatment for a Rare Form of Acute Leukemia
Health Canada has recently approved Trisenox® (arsenic trioxide) for relapsed or refractory acute promyelocytic leukemia. [Lundbeck Canada Inc.] Press Release

Gentium Receives EMA Orphan Drug Designation for Defibrotide for the Prevention of GvHD
Gentium S.p.A. announced that the European Commission (EC) has granted Orphan Drug Designation to defibrotide for the prevention of graft versus host disease (GvHD). [Gentium S.p.A.] Press Release

From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW International Society for Cellular Therapy 2014
April 23-26
Paris, France

NEW British Society for Haematology 2014
April 28-30
Birmingham, United Kingdom

Visit our events page to see a complete list of events in the hematopoiesis research community.
 
JOB OPPORTUNITIES
NEW PhD Student – Hematopoiesis and Immunopathology (Sanquin)

NEW Postdoctoral Position – Hematopoietic Stem Cell Research (Lund Stem Cell Center)

PhD Position – Cancer Systems Biology/Leukemia Research (Universitätsklinikum Frankfurt a.M.)

Director of Sponsored Programs (Wake Forest Institute for Regenerative Medicine)

Adult Stem Cell Transplant Physician (John Theurer Cancer Center)

Postdoctoral Position – Transcriptional Regulation in Normal and Malignant Hematopoiesis (Karolinska Institute)

Postdoctoral Position – Hematopoietic Stem Cell Biology (St. Jude Children’s Research Hospital)

Postdoctoral Position – Human Pluripotent and Hematopoietic Stem Cell Bioinformatics (Albert Einstein College Medicine)

Translational Clinician-Scientist – Stem Cell Transplantation (Boston Children’s Hospital)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Hematopoiesis News: Archives | Events | Contact Us